Experience with the use of various forms of zinc pyrithione for seborrheic dermatitis
- Authors: Markelova E.M.1, Kruglova L.S.2, Gryazeva N.V.2
-
Affiliations:
- Polyclinic № 5 of the Administrative Department of the President of the Russian Federation
- Central State Medical Academy of the Administrative Department of the President of the Russian Federation
- Issue: Vol 30, No 14 (2023)
- Pages: 130-134
- Section: Dermatology/allergology
- URL: https://journals.eco-vector.com/2073-4034/article/view/626263
- DOI: https://doi.org/10.18565/pharmateca.2023.14.130-134
- ID: 626263
Cite item
Open Access
Access granted
Abstract
Seborrheic dermatitis (SD) is a common multifactorial chronic recurrent inflammatory skin disease that occurs in children and adults, characterized by the formation of erythematous-squamous or papulosquamous rashes in areas with a high concentration of sebaceous glands. The pathogenesis of the disease is not fully understood, but it is assumed that it is associated with hypercolonization of the skin by opportunistic Malassezia yeast, a pronounced immune response to an increase in the fungal population, and genetic predisposition. Chronicity of the process and acute relapses have a significant impact on the quality of life of patients. It is possible to treat acute forms of SD and prolong stable remission with the drug zinc pyrithione. In the current retrospective study, the drug was used in 76 patients who were divided into 3 groups taking into account the clinical symptoms of the process. Depending on clinical symptom, patients were prescribed various dosage forms of zinc pyrithione: shampoo, cream, aerosol. The results of the therapy were assessed 2 weeks after the start of using the drug. The data obtained during the study confirm the literature that it is possible to achieve a pronounced improvement in the process and remission already on the 10–14th day.
Full Text
About the authors
E. M. Markelova
Polyclinic № 5 of the Administrative Department of the President of the Russian Federation
Email: kruglovals@mail.ru
ORCID iD: 0000-0001-5937-606X
Russian Federation, Moscow
Larisa S. Kruglova
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Author for correspondence.
Email: kruglovals@mail.ru
ORCID iD: 0000-0002-5044-5265
Dr. Sci. (Med.), Professor, Head of the Department of Dermatovenereology and Cosmetology
Russian Federation, MoscowN. V. Gryazeva
Central State Medical Academy of the Administrative Department of the President of the Russian Federation
Email: kruglovals@mail.ru
ORCID iD: 0000-0003-3437-5233
Russian Federation, Moscow
References
- Borda L.J., Perper M., Keri J.E. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatol Treat. 2019;30(2):158–69. doi: 10.1080/09546634.2018.1473554.
- Wikramanayake T.C., Borda L.J., Miteva M., Paus R. Seborrheic dermatitis – Looking beyond Malassezia. Exp Dermatol. 2019;28(9):991–1001. doi: 10.1111/exd.14006.
- Полонская А.С., Шатохина Е.А., Круглова Л.С. Себорейный дерматит: современные представления об этиологии, патогенезе и подходах к лечению. Клиническая дерматология и косметология. 2020;19(4):451–58.
- Gupta A.K., Versteeg S.G. Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. Am J Clin Dermatol. 2017;18(2):193–213. doi: 10.1007/s40257-016-0232-2.
- Araya M., Kulthanan K., Jiamton S. Clinical Characteristics and Quality of Life of Seborrheic Dermatitis Patients in a Tropical Country. Indian J Dermatol. 2015;60(5):519. doi: 10.4103/0019-5154.164410.
- Круглова Л.С., Маркелова Е.С. Себорейный дерматит волосистой части головы: от патогенеза к обоснованному лечению. Эффективная фармакотерапия. 2022;18 (31):16–20.
- De Souza Leao Kamamoto C., Sanudo A., Hassun K.M., Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017;56(1):80–5. doi: 10.1111/ijd.13408.
- Rademaker M. Low-Dose Isotretinoin for Seborrhoeic Dermatitis. J Cutan. Med Surg. 2017;21(2):170–71. doi: 10.1177/1203475416676806.
- Kastarinen H., Oksanen T., Okokon E.O., et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;2014(5):CD009446. doi: 10.1002/14651858.CD009446.pub2.
- Barak-Shinar D., Green L.J. Scalp Seborrheic Dermatitis and Dandruff Therapy Using a Herbal and Zinc Pyrithione-based Therapy of Shampoo and Scalp Lotion. J Clin Aesthet Dermatol. 2018;11(1):26–31.
- Schwartz J.R., Rocchetta H., Asawanonda P., et al. Does tachyphylaxis occur in long-term management of scalp seborrheic dermatitis with pyrithione zinc-based treatments? Int J Dermatol. 2009;48(1):79–85. doi: 10.1111/j.1365-4632.2009.03794.x.
- Hasanbeyzade S. The Effects of Zinc Pyrithione and Selenium Disulfide Shampoos on the Lesion-free Period After Treatment in Patients with Seborrheic Dermatitis. J Clin Aesthet Dermatol. 2023;16(5):40–2.
- Pierard-Franchimont C., Goffin V., Decroix J., Pierard G.E. A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002;15(6):434–41. doi: 10.1159/000066452.
- Панюкова С.В., Пирузян А.Л., Корсунская И.М. Себорейный дерматит: как помочь пациенту. Consilium Medicum. 2020;22(7):46–8. [Paniukova S.V., Piruzyan A.L., Korsunskaya I.M. Seborrheic dermatitis: how to help the patient. Consilium Medicum. 2020;22(7):46–8. (In Russ.)]. doi: 10.26442/20751753.2020. 7.200314.
- Круглова Л.С., Петрий М.Н., Генслер Е.М. Оценка эффективности применения активированного пиритион цинка в терапии больных псориазом. Клиническая дерматология и венерология. 2019;18(5):616–23. [Kruglova L.S., Petriy M.N., Gensler E.M. Assessment of efficiency of activated zinc pyrithione administration for treatment of psoriasis patients. Сlin Dermatol Venerol. 2019;18(5):616–23. (In Russ.)]. doi: 10.17116/klinderma201918051616.
- Панюкова С.В., Соркина И.Л., Лысенко В.В., Корсунская И.М. Рациональная терапия себорейного дерматита. Клиническая дерматология и венерология. 2012;10(4):61–5. [Paniukova S.V., Sorkina I.L., Lysenko V.V., Korsunskaia I.M. Rational therapy for seborrheic dermatitis. Сlin Dermatol Venerol. 2012;10(4):61–5. (In Russ.)].
- Полонская А.С., Шатохина Е.А., Круглова Л.С. Себорейный дерматит: современные представления об этиологии, патогенезе и подходах к лечению. Клиническая дерматология и венерология. 2020;19(4):451–58. [Polonskaya A.S., Shatokhina E.A., Kruglova L.S. Seborrheic dermatitis: current ideas of the etiology, pathogenesis, and treatment approaches. Clin Dermatol Venerol. 2020;19(4):451–58. (In Russ.)].
- Comert A., Bekiroglu N., Gurbuz O., Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol. 2007;8(4):235–38. doi: 10.2165/00128071-200708040-00005.
Supplementary files
